Section: Pathology

Original Research Article

CORRELATION BETWEEN HISTOPATHOLOGICAL FINDINGS AND CLINICAL OUTCOMES IN CHRONIC INFLAMMATORY BOWEL DISEASE

Madhavi Kolakonda[1], Roopa Dixith Nagasaram[2], Arshiya Firdous Mohammad[2], Pasam Ramana Kumari[3], Vijayasree Mandava[4]

[1]Assistant Professor, Department of Pathology, Guntur medical College, Guntur, Andhra Pradesh, India
[2]Assistant Professor, Department of Pathology, Siddhartha Medical College, Vijayawada, Andhra Pradesh, India
[3]Associate Professor, Department of Pathology, Guntur medical College, Guntur, Andhra Pradesh, India
[4]Professor and HOD, Department of Pathology, Siddhartha Medical College, Vijayawada, Andhra Pradesh, India

Received : *05/05/2024*
Received in revised form : *23/06/2024*
Accepted : *08/07/2024*

Keywords:
Inflammatory bowel disease, Crohn's disease, ulcerative colitis, histopathology, clinical outcomes, symptom severity, hospitalizations.

Corresponding Author:
Dr. Pasam Ramana Kumari,
Email: pasamramanakumari@gmail.com

DOI: 10.47009/jamp.2024.6.4.9

Source of Support: Nil,
Conflict of Interest: None declared

Int J Acad Med Pharm
2024; 6 (4); 36-40

Abstract

Background: This study investigates the correlation between histopathological findings and clinical outcomes in patients with chronic inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC). **Materials and Methods:** A total of 100 patients with IBD (58 with CD and 42 with UC) were included. Demographic data were collected, and histopathological features were analyzed from biopsy samples. Clinical outcomes were assessed based on symptom severity, hospitalizations, and surgical interventions over a 12-month follow-up period. Pearson correlation analysis was conducted to determine the relationship between histopathological findings and clinical outcomes. **Result:** The mean age of the patients was 45.3 years, with an age range of 18 to 78 years. Histopathological analysis revealed that in CD, 82% had transmural inflammation, 55% had non-caseating granulomas, and 60% had fissuring ulcers. In UC, 90% had mucosal and submucosal inflammation, 70% had crypt abscesses, and 85% had continuous colonic involvement. Clinical outcomes indicated that patients with severe histopathological findings had more severe symptoms, higher hospitalization rates, and a greater need for surgical intervention. For CD, the mean HBI score for severe cases was 12.5, with an average of 2.4 hospitalizations per year, and 35% requiring surgery. For UC, the mean Mayo Clinic Score for severe cases was 10.8, with 2.0 hospitalizations per year, and 28% requiring surgery. Strong positive correlations were found between histopathological severity and clinical outcomes in both CD and UC ($p < 0.01$). **Conclusion:** Severe histopathological findings in IBD are significantly correlated with worse clinical outcomes. These findings highlight the importance of comprehensive histopathological evaluation in the management and prognosis of IBD.

INTRODUCTION

Inflammatory bowel disease (IBD) is a chronic condition characterized by recurrent inflammation of the gastrointestinal tract, encompassing two primary forms: Crohn's disease (CD) and ulcerative colitis (UC).[1,2] Both subtypes present with distinct histopathological and clinical features, yet they share common symptoms such as abdominal pain, diarrhea, and weight loss, which significantly impact patients' quality of life.[3] The etiology of IBD remains incompletely understood, but it is believed to involve a complex interplay of genetic, environmental, and immunological factors.[4]

Histopathological examination of biopsy samples plays a crucial role in the diagnosis and management of IBD. Specific histopathological features, such as transmural inflammation and granulomas in CD and mucosal inflammation and crypt abscesses in UC, aid in distinguishing between the two diseases and assessing disease severity.[5,6] Despite the critical role of histopathology in IBD, the correlation between specific histopathological findings and clinical outcomes has not been extensively studied. Understanding this relationship could enhance disease management and prognostication, enabling more tailored therapeutic approaches.

ISSN (O): 2687-5365; ISSN (P): 2753-6556

Previous research has suggested that severe histopathological findings are associated with more aggressive disease courses and poorer clinical outcomes. However, these studies often had limited sample sizes and follow-up periods, necessitating further research to confirm these associations and explore their implications for patient care.

This study aims to investigate the correlation between histopathological findings and clinical outcomes in patients with chronic IBD, specifically focusing on CD and UC. By examining a cohort of 100 patients, we seek to provide a comprehensive analysis of how specific histopathological features correlate with symptom severity, frequency of hospitalizations, and the need for surgical interventions. The findings of this study may contribute to improved prognostic tools and personalized treatment strategies for IBD patients.

MATERIALS AND METHODS

Study Design and Setting: This study was conducted at Siddhartha Medical College, Vijayawada, from June 2022 to May 2023. It was designed as a retrospective cohort study, focusing on patients diagnosed with chronic inflammatory bowel disease (IBD), including both Crohn's disease (CD) and ulcerative colitis (UC).

Patient Selection: A total of 100 patients diagnosed with IBD were included in the study. The inclusion criteria were:

1. Confirmed diagnosis of CD or UC based on clinical, endoscopic, and histopathological findings.
2. Age between 18 and 78 years.
3. Availability of complete medical records for the study period.

Patients with incomplete medical records, those diagnosed with other forms of colitis, and those who had undergone surgical intervention prior to the study period were excluded.

Data Collection: Data were collected from the medical records of the patients, including demographic information (age, gender), clinical presentation, histopathological findings, and clinical outcomes. Histopathological findings were extracted from biopsy reports, while clinical outcomes were assessed based on symptom severity, frequency of hospitalizations, and the need for surgical interventions over a 12-month follow-up period.

Histopathological Assessment

Biopsy samples were obtained during colonoscopy and analyzed by experienced pathologists at Siddhartha Medical College. The histopathological features assessed included:

- For CD: Transmural inflammation, non-caseating granulomas, and fissuring ulcers.
- For UC: Mucosal and submucosal inflammation, crypt abscesses, and continuous colonic involvement.

Clinical Outcome Measures

Clinical outcomes were evaluated based on:

1. Symptom Severity: Assessed using the Harvey-Bradshaw Index (HBI) for CD and the Mayo Clinic Score for UC.
2. Frequency of Hospitalizations: Recorded as the number of hospitalizations related to IBD during the study period.
3. Surgical Interventions: Documented as any surgical procedures performed due to IBD complications during the study period.

Statistical Analysis

Data were analyzed using SPSS version 25.0. Descriptive statistics were used to summarize demographic characteristics, histopathological findings, and clinical outcomes. Pearson correlation analysis was conducted to assess the relationship between histopathological findings and clinical outcomes. A p-value of <0.05 was considered statistically significant.

Ethical Considerations

The study was approved by the Institutional Ethics Committee of Siddhartha Medical College, Vijayawada. Informed consent was waived due to the retrospective nature of the study. Patient confidentiality was maintained by anonymizing all data before analysis.

RESULTS

Demographic Characteristics

The study included a total of 100 patients diagnosed with chronic inflammatory bowel disease (IBD), comprising 58 with Crohn's disease (CD) and 42 with ulcerative colitis (UC). The mean age of the participants was 45.3 years, with an age range of 18 to 78 years. The gender distribution was nearly equal, with 52 males and 48 females [Table 1].

Histopathological Findings

Histopathological analysis revealed distinct differences between CD and UC patients. In CD, the most common features included transmural inflammation (82%), non-caseating granulomas (55%), and fissuring ulcers (60%). In contrast, UC patients predominantly exhibited mucosal and submucosal inflammation (90%), crypt abscesses (70%), and continuous colonic involvement (85%) [Table 2].

Clinical Outcomes

Clinical outcomes were evaluated based on the severity of symptoms, frequency of hospitalizations, and the need for surgical intervention. The severity of symptoms was assessed using the Harvey-Bradshaw Index (HBI) for CD and the Mayo Clinic Score for UC. Patients with severe histopathological findings in CD had a mean HBI score of 12.5, compared to 7.3 in those with milder findings. For UC, the mean Mayo Clinic Score was 10.8 for severe cases and 5.9 for milder cases.

The frequency of hospitalizations correlated with the severity of histopathological findings. CD patients

ISSN (O): 2687-5365; ISSN (P): 2753-6556

with severe histopathological features had an average of 2.4 hospitalizations per year, whereas those with milder findings had 1.1 hospitalizations per year. Similarly, UC patients with severe histopathological features had an average of 2.0 hospitalizations per year compared to 0.9 for those with milder findings. The need for surgical intervention was higher among patients with severe histopathological findings. In CD, 35% of patients with severe findings required surgery, compared to 15% with milder findings. For UC, 28% of patients with severe histopathological findings required surgical intervention, compared to 10% with milder findings [Table 3].



Figure 1: Histopathological Findings in Crohn's Disease and Ulcerative Colitis

Correlation Analysis

A Pearson correlation analysis demonstrated significant positive correlations between the severity of histopathological findings and clinical outcomes. In CD, the severity of histopathological findings strongly correlated with symptom severity ($r = 0.72$, $p < 0.01$), frequency of hospitalizations ($r = 0.65$, $p < 0.01$), and the need for surgical intervention ($r = 0.60$, $p < 0.01$). Similarly, in UC, there were strong correlations between histopathological severity and symptom severity ($r = 0.70$, $p < 0.01$), frequency of hospitalizations ($r = 0.62$, $p < 0.01$), and the need for surgical intervention ($r = 0.58$, $p < 0.01$) [Table 4].



Figure 2: Clinical Outcomes in Crohn's Disease and Ulcerative Colitis



Figure 3: Correlation Analysis in Crohn's Disease and Ulcerative Colitis

Table 1: Demographic Characteristics of the Study Population.

Characteristic	Crohn's Disease (CD)	Ulcerative Colitis (UC)	Total
Number of Patients	58	42	100
Mean Age (years)	44.7	46.1	45.3
Age Range (years)	18-78	20-75	18-78
Male (%)	30 (51.7%)	22 (52.4%)	52
Female (%)	28 (48.3%)	20 (47.6%)	48

Table 2: Histopathological Findings

Finding	Crohn's Disease (CD) (%)	Ulcerative Colitis (UC) (%)
Transmural Inflammation	82	-
Non-caseating Granulomas	55	-
Fissuring Ulcers	60	-
Mucosal and Submucosal Inflammation	-	90
Crypt Abscesses	-	70
Continuous Colonic Involvement	-	85

Table 3: Clinical Outcomes

Outcome	Crohn's Disease (CD)	Ulcerative Colitis (UC)
Mean HBI Score (Severe Cases)	12.5	-
Mean HBI Score (Milder Cases)	7.3	-
Mean Mayo Clinic Score (Severe Cases)	-	10.8
Mean Mayo Clinic Score (Milder Cases)	-	5.9
Average Hospitalizations/Year (Severe Cases)	2.4	2.0
Average Hospitalizations/Year (Milder Cases)	1.1	0.9
Surgical Interventions (%) (Severe Cases)	35	28
Surgical Interventions (%) (Milder Cases)	15	10

ISSN (O): 2687-5365; ISSN (P): 2753-6556

Table 4: Correlation Analysis

Correlation	Crohn's Disease (CD)	Ulcerative Colitis (UC)
Symptom Severity	$r = 0.72$, $p < 0.01$	$r = 0.70$, $p < 0.01$
Frequency of Hospitalizations	$r = 0.65$, $p < 0.01$	$r = 0.62$, $p < 0.01$
Need for Surgical Intervention	$r = 0.60$, $p < 0.01$	$r = 0.58$, $p < 0.01$

DISCUSSION

The present study aimed to investigate the correlation between histopathological findings and clinical outcomes in patients with chronic inflammatory bowel disease (IBD), specifically focusing on Crohn's disease (CD) and ulcerative colitis (UC). The results indicate a significant relationship between the severity of histopathological features and clinical outcomes, including symptom severity, frequency of hospitalizations, and the need for surgical interventions. This correlation underscores the importance of histopathological assessment in understanding disease progression and tailoring patient management strategies.[7]

Key Findings

Our findings demonstrate that patients with more severe histopathological findings tend to experience worse clinical outcomes.[8] In CD, features such as transmural inflammation, non-caseating granulomas, and fissuring ulcers were strongly correlated with higher Harvey-Bradshaw Index (HBI) scores, increased hospitalizations, and a greater need for surgical intervention. This indicates that the depth and extent of inflammation, along with specific pathological markers like granulomas and ulcers, play a critical role in determining the clinical severity of CD. Similarly, in UC, severe mucosal and submucosal inflammation, crypt abscesses, and continuous colonic involvement were associated with higher Mayo Clinic Scores, more frequent hospitalizations, and higher rates of surgery. These findings suggest that the extent of mucosal damage and the presence of crypt abscesses are pivotal in exacerbating UC symptoms and complications.[9-11]

These results are consistent with previous studies that have highlighted the prognostic value of histopathological features in IBD. For instance, Christensen et al. (2017) noted that severe histopathological findings are indicative of a more aggressive disease course and poorer clinical outcomes. Additional studies have also confirmed that more pronounced histopathological changes are linked to an increased likelihood of adverse clinical events and interventions (Soleymani et al, 2020; Fabian & Bajer, 2022).[9,10] These studies collectively emphasize that histopathological severity is a strong predictor of clinical deterioration and the need for intensive medical or surgical intervention. Our study reinforces these observations and extends them by providing a comprehensive analysis of 100 patients over a 12-month period. The large sample size and the extended follow-up period add robustness to our findings, supporting the notion that detailed histopathological evaluation is crucial for predicting clinical outcomes in IBD patients.[12,13]

Clinical Implications

The significant correlations observed in this study underscore the importance of thorough histopathological evaluation in the management of IBD. Histopathological findings can serve as valuable prognostic indicators, guiding clinicians in tailoring treatment strategies. For example, patients with severe histopathological features may benefit from more aggressive therapeutic interventions to mitigate symptom severity and reduce the risk of complications requiring hospitalization or surgery.[14] Furthermore, these findings highlight the need for regular monitoring and re-evaluation of histopathological changes in IBD patients. Such an approach could enable early identification of patients at risk of disease progression, allowing for timely adjustments in their management plans.

Limitations

Despite the significant findings, this study has several limitations. The retrospective design may introduce selection bias, and the relatively small sample size limits the generalizability of the results. Additionally, the study was conducted at a single medical center, which may not reflect the broader population of IBD patients. Future studies with larger, multicenter cohorts are necessary to validate these findings and further explore the relationship between histopathological severity and clinical outcomes.

Future Directions

Future research should focus on longitudinal studies that track histopathological changes over time and their impact on long-term clinical outcomes. Additionally, investigating the molecular and genetic underpinnings of histopathological features in IBD could provide deeper insights into disease mechanisms and potential therapeutic targets.

CONCLUSION

Our study establishes a significant correlation between histopathological findings and clinical outcomes in chronic inflammatory bowel disease. Patients with severe histopathological features exhibit more severe symptoms, higher hospitalization rates, and a greater need for surgical intervention. These findings underscore the critical role of histopathological evaluation in the management and prognosis of IBD, advocating for a more personalized approach to treatment based on histopathological severity.

REFERENCES

1. Kim DB, Lee KM, Lee JM, Chung YY, Sung HJ, Paik CN, Chung WC, Jung JH, Choi HJ. Correlation between Histological Activity and Endoscopic, Clinical, and Serologic

ISSN (O): 2687-5365; ISSN (P): 2753-6556

Activities in Patients with Ulcerative Colitis. Gastroenterol Res Pract. 2016;2016:5832051. doi: 10.1155/2016/5832051. Epub 2015 Dec 29. PMID: 26839541; PMCID: PMC4709652.
2. McDowell C, Farooq U, Haseeb M. Inflammatory Bowel Disease. [Updated 2023 Aug 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470312/
3. Villanacci V, Reggiani-Bonetti L, Salviato T, Leoncini G, Cadei M, Albarello L, Caputo A, Aquilano MC, Battista S, Parente P. Histopathology of IBD Colitis. A practical approach from the pathologists of the Italian Group for the study of the gastrointestinal tract (GIPAD). Pathologica. 2021 Feb;113(1):39-53. doi: 10.32074/1591-951X-235. PMID: 33686309; PMCID: PMC8138698.
4. Jucan AE, Gavrilescu O, Dranga M, Popa IV, Mihai IR, Mihai VC, Stefanescu G, Drug VL, Prelipcean CC, Vulpoi RA, Barboi OB, Ciortescu I, Mihai C. Evaluation of Disease Activity in Inflammatory Bowel Disease: Diagnostic Tools in the Assessment of Histological Healing. Biomedicines. 2023 Nov 18;11(11):3090. doi: 10.3390/biomedicines11113090. PMID: 38002090; PMCID: PMC10669373.
5. Vespa E, D'Amico F, Sollai M, Allocca M, Furfaro F, Zilli A, Dal Buono A, Gabbiadini R, Danese S, Fiorino G. Histological Scores in Patients with Inflammatory Bowel Diseases: The State of the Art. J Clin Med. 2022 Feb 11;11(4):939. doi: 10.3390/jcm11040939. PMID: 35207211; PMCID: PMC8880199.
6. Park S, Abdi T, Gentry M, Laine L. Histological Disease Activity as a Predictor of Clinical Relapse Among Patients With Ulcerative Colitis: Systematic Review and Meta-Analysis. Am J Gastroenterol. 2016 Dec;111(12):1692-1701. doi: 10.1038/ajg.2016.418. Epub 2016 Oct 11. PMID: 27725645.
7. Lang-Schwarz C, Angeloni M, Agaimy A, Atreya R, Becker C, Dregelies T, . Validation of the 'Inflammatory Bowel Disease-Distribution, Chronicity, Activity [IBD-DCA] Score' for Ulcerative Colitis and Crohn´s Disease. J Crohns Colitis. 2021 Oct 7;15(10):1621-1630. doi: 10.1093/ecco-jcc/jjab055. PMID: 33773497; PMCID: PMC8495487.
8. Christensen B, Hanauer SB, Erlich J, Kassim O, Gibson PR, Turner JR, Hart J, Rubin DT. Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes. Clin Gastroenterol Hepatol. 2017 Oct;15(10):1557-1564.e1. doi: 10.1016/j.cgh.2017.02.016. Epub 2017 Feb 24. PMID: 28238954; PMCID: PMC5618439.
9. Soleymani S, Moradkhani A, Eftekhari M, Rahmanian F, Moosavy SH. Correlation between Clinical Symptoms and Lab Tests with Endoscopic Severity Indexes in Patients with Inflammatory Bowel Diseases. Middle East J Dig Dis. 2020 Jul;12(3):162-170. doi: 10.34172/mejdd.2020.178. PMID: 33062221; PMCID: PMC7548093.
10. Fabian O, Bajer L. Histopathological assessment of the microscopic activity in inflammatory bowel diseases: What are we looking for? World J Gastroenterol. 2022 Sep 28;28(36):5300-5312. doi: 10.3748/wjg.v28.i36.5300. PMID: 36185628; PMCID: PMC9521520.
11. Verstockt B, Pouillon L, Ballaux F, Jorissen C, Hoefkens E, Lembrechts N, Bossuyt P. Patient-reported Outcomes and Disability Are Associated with Histological Disease Activity in Patients with Ulcerative Colitis: Results from the APOLLO Study. J Crohns Colitis. 2023 Jul 5;17(7):1046-1054. doi: 10.1093/ecco-jcc/jjad015. PMID: 36708189.
12. Shetty S, Anjarwalla SM, Gupta J, Foy CJ, Shaw IS, Valori RM, Shepherd NA. Focal active colitis: a prospective study of clinicopathological correlations in 90 patients. Histopathology. 2011 Nov;59(5):850-6. doi: 10.1111/j.1365-2559.2011.04019.x. PMID: 22092396.
13. Rodrigues BL, Mazzaro MC, Nagasako CK, Ayrizono MLS, Fagundes JJ, Leal RF. Assessment of disease activity in inflammatory bowel diseases: Non-invasive biomarkers and endoscopic scores. World J Gastrointest Endosc. 2020 Dec 16;12(12):504-520. doi: 10.4253/wjge.v12.i12.504. PMID: 33362904; PMCID: PMC7739141.
14. Christensen B. Histologic Healing in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2022 Aug;18(8):466-468. PMID: 36397814; PMCID: PMC9666803.

ISSN (O): 2687-5365; ISSN (P): 2753-6556